https://charts.traderzeitung.de/phases/US1266381052 string(1442) "{"isin":"US1266381052","name":"CVRx Inc","stock_id_xnas":22560424,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.97,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.94,"close_at":"2026-09-22 01:53:00","complete":true,"perf_pct":-1.0101}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.87,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-2.381},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.88,"close_at":"2026-09-22 22:46:00","complete":true,"perf_pct":0.3484}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.72,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-5.5556},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.74,"close_at":"2026-09-23 22:19:00","complete":false,"perf_pct":0.7353}]}]}"

CVRx Aktie News & Nachrichten

[WKN: A3CTH9 | Symbol: CVRX]

Realtimekurs

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über CVRx gefunden werden.

CVRx Nachrichtenticker öffnen

MT Newswires 21.09.2026 22:34 Uhr

CVRx Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Nyxoah ernennt Loic Moreau zum Interims-CFO, da John Landry zurücktritt

CVRx ernennt neuen Finanzvorstand

Größte Verlierer am Mittag

Piper Sandler stuft CVRx von Overweight auf Neutral herab und passt das Kursziel von $12 auf $4 an

Die stärksten Verlierer vorbörslich

CVRx sagt, Finanzvorstand Jared Oasheim wird zurücktreten